Stockscreener 앱 받기
2.13
1.39%
-0.03
전일 마감가:
$2.16
열려 있는:
$2.16
하루 거래량:
152.08K
Relative Volume:
0.88
시가총액:
$80.11M
수익:
-
순이익/손실:
$-13.27M
주가수익비율:
-12.99
EPS:
-0.164
순현금흐름:
$-7.70M
1주 성능:
-0.93%
1개월 성능:
+7.04%
6개월 성능:
-22.55%
1년 성능:
+105.80%
1일 변동 폭
$2.09
$2.184
1주일 범위
$1.9713
$2.49
52주 변동 폭
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.13 | 81.24M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO Pharma stock gets FDA compassionate use approval for urcosimod By Investing.com - Investing.com South Africa
OKYO Pharma stock gets FDA compassionate use approval for urcosimod - Investing.com
FDA Approves Single-Patient Compassionate Use of Urcosimod for the Treatment of Neuropathic Corneal Pain - VisionMonday
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain - Sahm
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain By Investing.com - Investing.com India
Small cap wrap: Medicus Pharma, OKYO, American Resources... - Proactive financial news
FDA authorizes expanded access use of OKYO Pharma’s urcosimod for single patient By Investing.com - Investing.com South Africa
OKYO Pharma gets FDA nod for compassionate use of eye drug in neuropathic corneal pain - Proactive Investors
FDA authorizes expanded access use of OKYO Pharma’s urcosimod for single patient - Investing.com
Okyo announces FDA authorized single-patient expanded IND for urcosimod - TipRanks
OKYO Pharma Wins FDA Compassionate-Use Clearance for Urcosimod in Severe Neuropathic Corneal Pain - TipRanks
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain - Investing.com
FDA authorizes compassionate use for OKYO’s nerve pain med - grafa.com
Aug Summary: Is OKYO Pharma Limited a turnaround storyQuarterly Growth Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Portfolio Shifts: Can OKYO Pharma Limited beat the S P 500Trade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Market Trends: Can OKYO Pharma Limited beat the S P 500Gap Down & Smart Investment Allocation Insights - baoquankhu1.vn
Leadership watch: OKYO, Orbis, and BVI Medical name new CEOs - Eyes On Eyecare
Will OKYO Pharma Limited stock recover faster than marketJuly 2025 Opening Moves & Daily Volume Surge Signals - bollywoodhelpline.com
Published on: 2026-01-18 23:27:28 - baoquankhu1.vn
Can Whitehawk Therapeutics Inc sustain its profitability2025 Pullback Review & Weekly Sector Rotation Insights - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
OKYO Pharma (NASDAQ:OKYO) Trading Down 15.5%What's Next? - MarketBeat
Published on: 2026-01-13 10:43:18 - baoquankhu1.vn
Aug Technicals: Can OKYO Pharma Limited maintain sales growth2025 Stock Rankings & Verified Momentum Stock Ideas - baoquankhu1.vn
Risk Hedge: Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Return Stock Opportunities - moha.gov.vn
Is OKYO Pharma Limited stock affected by interest rate hikes2025 Growth vs Value & Weekly High Conviction Ideas - ulpravda.ru
Dividend Watch: Will OKYO Pharma Limited stock benefit from green energy trendsMarket Volume Report & Daily Profit Maximizing Tips - Улправда
Can OKYO Pharma Limited stock resist market sell offsSell Signal & Technical Confirmation Alerts - ulpravda.ru
Will OKYO Pharma Limited stock benefit from green energy trendsQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда
Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 Patterns & Real-Time Buy Signal Alerts - Улправда
Will OKYO Pharma Limited stock outperform growth indexesStop Loss & Detailed Earnings Play Strategies - Улправда
Will OKYO Pharma Limited stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - Улправда
Entry Recap: Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 PostEarnings & Fast Gain Swing Trade Alerts - Улправда
What Wall Street predicts for OKYO Pharma Limited stock priceQuarterly Trade Review & Weekly Top Stock Performers List - Улправда
Is OKYO Pharma Limited stock trading at a premium valuationTechnical Pattern Recognition & Identify Winning Stocks - ulpravda.ru
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com Nigeria
OKYO Pharma appoints Robert Dempsey as new CEO By Investing.com - Investing.com Nigeria
OKYO Pharma Limited's (NASDAQ:OKYO) Intrinsic Value Is Potentially 90% Above Its Share Price - Yahoo Finance
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential - TipRanks
OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO - Proactive financial news
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO - Proactive financial news
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - BioSpace
OKYO Pharma names Robert J. Dempsey as chief executive officer By Investing.com - Investing.com India
OKYO Pharma names Robert J. Dempsey as chief executive officer - Investing.com
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase - TipRanks
OKYO Pharma appoints Robert Dempsey as new CEO - Investing.com
OKYO Pharma names ophthalmology veteran Robert J Dempsey as CEO to drive next growth phase - MSN
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):